Sangamo Biosciences reported $-43919000 in Pre-Tax Profit for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Alnylam Pharmaceuticals ALNY:US $ -239.36M 20.95M
Amgen AMGN:US $ 2727M 56M
Biocryst Pharmaceuticals BCRX:US $ -73.92M 58.39M
Biogen BIIB:US $ 903.4M 316.6M
Biomarin Pharmaceutical BMRN:US $ 26.19M 92.76M
Bluebird Bio BLUE:US $ -122.15M 10.09M
Intercept Pharmaceuticals ICPT:US $ -17.28M 19M
IONIS PHARMACEUT IONS:US $ -64M 289M
Johnson & Johnson JNJ:US $ 8218M 1879M
Karyopharm Therapeutics KPTI:US $ -41269000 79.87M
Merk MRK:US $ 6309M 1525M
Novartis NOVN:VX SF 3912M 230M
Omeros OMER:US $ -39494000 7.82M
Pfizer PFE:US $ 11328M 4083M
Regulus Therapeutics RGLS:US $ -6.72M 0.42M
Sangamo Biosciences SGMO:US $ -43.92M 6.36M
Sanofi SAN:FP € 2965M 804M
Sarepta Therapeutics SRPT:US $ -104.15M 17.74M
Ultragenyx Pharmaceutical RARE:US $ -151.76M 29.32M
Ziopharm Oncology ZIOP:US $ -9.79M 2M